CASSAVA SCI (SAVA)
$1.20
0.01 (0.83%)
SAVA Stock Quote Delayed 30 Minutes
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
Cassava is still enrolling patients in its Phase 3 study of the drug, which has a different target than Biogen's Leqembi.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$1.31
Market Cap
63.28M
PE Ratio
-2.30
EPS
-0.5225
Volume (Avg. Vol.)
801,235
Day's Range
$1.19 - $1.35
52-Week Range
$1.17 - $42.20
Dividend & Yield
N/A (N/A)
SAVA Stock Predictions, Articles, and CASSAVA SCI News
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
Today, shareholders in Cassava Sciences and SAVA stock are cheering some positive research data for its key drug candidate.
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule.
Is a Short Squeeze Coming in Cassava Sciences (SAVA) Stock?
Today, a rally across most meme stocks has investors looking at Cassava Sciences and SAVA stock due to the short interest in this stock.
Why Is Cassava Sciences (SAVA) Stock Up 10% Today?
Cassava Sciences has completed part of an important Alzheimer’s disease treatment trial. Here's why SAVA stock may rise even more soon.
Why Is Cassava Sciences (SAVA) Stock Up Today?
Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.
Cassava Sciences Has a Big Warning for SAVA Stock Short Sellers
SAVA stock is in the green after reporting earnings. The company also filed a lawsuit against short sellers, alleging misleading statements.
What the Latest Controversy Really Means for SAVA Stock
Headlines and controversy notwithstanding, consider SAVA stock to be one of the more promising biotech plays out there.
Why Is Cassava Sciences (SAVA) Stock Down 10% Today?
SAVA stock is in the red after a piece from Probes Reporter accused Cassava of being involved with two undisclosed SEC investigations.
A New Study Makes Cassava Sciences Stock an Interesting Buy
Making progress with what could ultimately be a breakthrough treatment, consider SAVA stock a great speculative buy, whether now, or on further weakness.
SAVA Stock Alert: Cassava Sciences Extends Trial
SAVA stock is in focus after Cassava announced that it would begin an open-label study of its investigational Alzheimer's drug, simufilam.
Don’t Let Misconduct Allegations Cloud Your Perception of SAVA Stock
It's easy to get mired in the controversy surrounding Cassava Sciences, but distracted SAVA stock traders might miss an opportunity.
How High Can SAVA Stock Go Once the Controversy Clears?
If a reproduced SEC letter concerning Cassava Sciences' clearance is legit, SAVA stock could head much higher.
Why Is Cassava Sciences (SAVA) Stock Heating Up Today?
SAVA stock rose 5% on the success of Biogen in slowing cognitive decline from Alzheimer's, but its Simufilam has a different target.
